Former Genentech CEO Levinson joins Amyris' board

> AVI BioPharma's board has appointed CFO J. David Boyle II as interim president and CEO. The appointment follows former CEO and director Leslie Hudson's resignation. The board plans to initiate a search for CEO candidates, which will include both external and internal candidates. AVI release

> Amyris Biotechnologies announced that former Genentech CEO Arthur Levinson, Ph.D, is joining the company's board of directors. Amyris release

> Sigma Pharmaceuticals says CEO and Managing Director Elmo De Alwis has resigned both positions. He will continue in the role until the board has identified and appointed his replacement. Sigma release

> Sangamo BioSciences has appointed William Ringo as chairman of the company's board of directors effective April 16, 2010. Sangamo release

> Shareholders of Cumberland Pharmaceuticals have elected Gordon R. Bernard, M.D., Jonathan Griggs, and James Jones as new members of the company's board of directors at its annual meeting. Directors A.J. Kazimi and Martin E. Cearnal were also re-elected. Cumberland release

> Richard Ranieri has joined Dendreon as senior vice president of human resources, effective April 19, 2010. Dendreon release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.